BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer
This study has been completed.
Information provided by (Responsible Party):
howard safran, Brown University
First received: February 22, 2007
Last updated: July 1, 2013
Last verified: July 2013
Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer
Drug: Cetuximab,Paclitaxel, Carboplatin
||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer BMS#CA225091
Primary Outcome Measures:
Secondary Outcome Measures:
- Measure of Safety and Tolerability According to CTC Version 3.0 [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||April 2010 (Final data collection date for primary outcome measure)
etuximab, paclitaxel, and carboplatin weekly for 6 weeks with 50.4 Gy radiation.
Drug: Cetuximab,Paclitaxel, Carboplatin
IV treatment for 6 weeks
The primary objective of this phase II trial is to estimate the rate of complete pathologic response as determined by surgical resection or post treatment endoscopy (for patients not undergoing resection) for the treatment regimen being tested. With a total accrual of 28 evaluable patients.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Patients are required to have pathologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus, gastroesophageal junction, or stomach.
- Patients may have mediastinal, celiac adenopathy, peri-portal and regional gastric lymphadenopathy.
- There must be no evidence of distant organ metastases.
- No prior radiation for gastric or esophageal cancer.
- Patients must be > 18 years of age, and nonpregnant
- Patients must have an ANC > 1,500/ul, platelets > 100,000/ul, creatinine < 2 x upper limit normal (ULN) and bilirubin < 1.5 x ULN, and AST < 3 x ULN.
- ECOG performance status 0-2.
- Patients must not have significant infection or other coexistent medical condition that would preclude protocol therapy.
- Female patients, must either be not of child bearing potential or have a negative pregnancy test within 7 days of starting study treatment. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal. Pregnant or lactating females are not eligible.
- All patients must sign informed consent
Any of the following criteria will make the patient ineligible to participate in this study:
- Acute hepatitis or AIDS.
- Active or uncontrolled infection.
- Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection fraction.
- Prior therapy which specifically and directly targets the EGFR pathway.
- Prior severe infusion reaction to a monoclonal antibody.
- Any concurrent chemotherapy not indicated in the study protocol or any other investigational agent(s).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00439608
|Brown University Oncology Group
|Providence, Rhode Island, United States, 02912 |
||Howard Safran, MD
||Brown University Oncology Research Group
No publications provided
||howard safran, Principle Investigator, Brown University
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 22, 2007
|Results First Received:
||May 9, 2013
||July 1, 2013
||United States: Institutional Review Board
Keywords provided by Brown University:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 03, 2013
Digestive System Diseases
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Phytogenic